Over 18 million people are diagnosed with cancer in the United States and approximately 50% report clinical levels of depression and/or anxiety, pain, and/or fatigue.1-2
I recently attended a dinner party where guests lamented the use of generative AI in schools. They asked questions like, “Will kids stop learning and plug all their essay prompts into ChatGPT?”
For many women, a confirmation of pregnancy tends to evoke numerous emotions: excitement, shock, nervousness, joy, gratitude, and sometimes, even surprise. It is a moment dreamed, prayed, and planned for—but not for all.
The initial foray into genomic sequencing two decades ago has led to the discovery of key driver mutations and spurred drug development, thereby transforming the management of imminently lethal diseases.
While overall cancer death rates have been dropping, the number of individuals being diagnosed with cancer has been going up, with younger patients increasingly affected.
CAR T-cell therapies have been used to treat cancer patients since 2011, but infection-related adverse events remain a significant hurdle. Often, fever is one of the earliest warning signs of clinical deterioration and a potentially life-threatening condition.
To provide a roadmap for accelerating progress against breast cancer over the next 10 years, an expert panel was convened at the 2022 San Antonio Breast Cancer Symposium to identify the biggest obstacles hindering our ability to cure breast cancer and to propose transformative solutions to address these obstacles.
The majority of epithelial ovarian cancer is diagnosed at an advanced stage and long-term survival is low. Since ovarian cancer screening is ineffective, the main focus to reduce ovarian cancer mortality is prevention.
The National Cancer Institute defines precision medicine in cancer as a strategy that “uses specific information about a person’s tumor to help make a diagnosis, plan treatment, find out how well treatment is working, or make a prognosis.”1
The release of FDA’s draft guidance, “Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases,” has been greatly anticipated since June 2021, when FDA announced in its accelerated approval of the KRASG12C inhibitor sotorasib that it would require a randomized, controlled trial comparing the efficacy of the labeled dose (960 mg once daily) to a 75% lower dose (240 mg once daily) as a condition of full regulatory approval (The Cancer Letter, June 11, 2021; April 29, 2022).
